Variability of platelet aggregate dispersal with glycoprotein IIb-IIIa antagonists eptifibatide and abciximab

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 6, 2009, Pages 983-991

  Speich, H E ^a,b   Earhart, A D ^a   Hill, S N ^a   Cholera, S ^a   Kueter, T J ^a   Smith, J N ^a   White, M M ^a   Jennings, Lisa K ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b University of Memphis   (United States)

Author keywords

Abciximab; Acute coronary syndromes; Disaggregation; Eptifibatide; GPIIb IIIa; Platelets

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST;

AGGREGOMETRY; ARTERY BLOOD FLOW; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE MEMBRANE;

ANTIBODIES, MONOCLONAL; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 65849492847     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03432.x     Document Type: Article

References (26)

1. Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, Tcheng JE, Lincoff AM, Hasselblad V, Topol EJ. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98: 2829-35.
2. Tricoci P, Peterson ED, Chen AY, Newby LK, Harrington RA, Greenbaum AB, Cannon CP, Gibson CM, Hoekstra JW, Pollack CV, Jr, Ohman EM, Gibler WB, Roe MT. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). Am J Cardiol 2007; 99: 1389-93.
3. Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, Baldazzi F, Dall'Ara G, Nardini P, Gianstefani S, Guastaroba P, Grilli R, Branzi A. Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: Results of a registry study in an ST-elevation myocardial infarction network. Eur Heart J 2009; 30: 33-43.
4. Moser M, Bertram U, Peter K, Bode C, Ruef J. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. J Cardiovasc Pharmacol 2003; 41: 586-92.
5. Marciniak SJ, Jr, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, Jordan RE, Marchese PJ, Frelinger AL. An additional mechanism of action of abciximab: Dispersal of newly formed platelet aggregates. Thromb Haemost 2002; 87: 1020-5.
6. Goto S, Tamura N, Ishida H. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol 2004; 44: 316-23.
7. Collet JP, Montalescot G, Lesty C, Soria J, Mishal Z, Thomas D, Soria C. Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol 2001; 21: 142-8.
8. Otterstad JE, Brosstad F. Results from clinical trials on ST-elevation myocardial infarction in a historic perspective with some pathophysiological aspects. Scand Cardiovasc J 2003; 37: 316-23.
9. White MM, Jennings LK. Laboratory evaluation of platelet function. In: Platelet Protocols. San Diego: Academic Press, 1999: 39-40.
10. White MM, Krishnan R, Kueter TJ, Jacoski MV, Jennings LK. The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIB-IIIa antagonists. J Thromb Thrombolysis 2004; 18: 163-9.
11. Wang Y, Sakuma M, Chen Z, Ustinov V, Shi C, Croce K, Zago AC, Lopez J, Andre P, Plow E, Simon DI. Leukocyte engagement of platelet glycoprotein Ibalpha via the integrin Mac-1 is critical for the biological response to vascular injury. Circulation 2005; 112: 2993-3000.
12. Speich HE, Grgurevich S, Kueter TJ, Earhart AD, Slack SM, Jennings LK. Platelets undergo phosphorylation of Syk at Y525/526 and Y352 in response to pathophysiological shear stress. Am J Physiol Cell Physiol 2008; 295: C1045-54.
13. Wencel-Drake JD, Boudignon-Proudhon C, Dieter MG, Criss AB, Parise LV. Internalization of bound fibrinogen modulates platelet aggregation. Blood 1996; 87: 602-12.
14. Quinn MJ, Murphy RT, Dooley M, Foley JB, Fitzgerald DJ. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion. J Pharmacol Exp Ther 2001; 297: 496-500.
15. Jennings LK, Tardiff B, Kitt M, Gretler B. Comparison of receptor occupancy and platelet aggregation response of eptifibatide administered intravenously in patients with unstable angina or non-Q wave myocardial infarction. J Am Coll Cardiol 1998; 31(Suppl. A): 353A.
16. Gretler DD, Guerciolini R, Williams PJ. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. Clin Ther 2004; 26: 390-8.
17. Gilchrist IC. Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: Focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide. Clin Pharmacokinet 2003; 42: 703-20.
18. Saucedo JF, Lui HK, Garza L, Guerra GJ, Jacoski MV, Jennings LK. Comparative pharmacodynamic evaluation of eptifibatide and abciximab in patients with non-ST-segment elevation acute coronary syndromes: The TAM2 study. J Thromb Thrombolysis 2004; 18: 67-74.
19. Jennings LK, Jacoski MV, White MM. The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors. J Interv Cardiol 2002; 15: 45-60.
20. Kimmelstiel C, Badar J, Covic L, Waxman S, Weintraub A, Jacques S, Kuliopulos A. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: Implications for adjustment of tirofiban and clopidogrel dosage. Thromb Res 2005; 116: 55-66.
21. Frojmovic M, Labarthe B, Legrand C. Inhibition and reversal of platelet aggregation by alphaIIbbeta3 antagonists depends on the anticoagulant and flow conditions: Differential effects of Abciximab and Lamifiban. Br J Haematol 2005; 131: 348-55.
22. Chandler AB, Earhart AD, Speich HE, Kueter TJ, Hansen J, White MM, Jennings LK. Regulation of CD40L (CD154) and CD62P (p-selectin) surface density by GPIIb-IIIa blockade of platelets from stable coronary artery disease patients. Thrombosis Research. In Press, 2009.
23. Mager DE, Mascelli MA, Kleiman NS, Fitzgerald DJ, Abernethy DR. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J Pharmacol Exp Ther 2003; 307: 969-76.
24. Kereiakes DJ, Broderick TM, Roth EM, Whang D, Mueller M, Lacock P, Anderson LC, Howard W, Blanck C, Schneider J, Abbottsmith CA. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists. J Thromb Thrombolysis 2000; 9: 149-55.
25. Abernethy DR, Pezzullo J, Mascelli MA, Frederick B, Kleiman NS, Freedman J. Pharmacodynamics of abciximab during angioplasty: Comparison to healthy subjects. Clin Pharmacol Ther 2002; 71: 186-95.
26. Deibele AJ, Kirtane AJ, Pinto DS, Lucca MJ, Neva C, Shui A, Murphy SA, Tcheng JE, Gibson CM. Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. J Thromb Thrombolysis 2006; 22: 47-50.